Prediction of relapses of endometrial hyperplasia without atypia

• Mekan R. Orazov
• Lyudmila M. Mikhaleva
• Irina A. Mullina
• Zarina S. Aivazova

Abstract

Number of patients with endometrial cancer is increasing every year. Unfortunately, the diagnosis of endometrial cancer often occurs at a late stage, which complicates subsequent tactics of patient management and prognosis. Endometrial hyperplasia, particularly atypical endometrial hyperplasia, is a true precancerous disease, so predicting the outcome will help to prevent malignization and restore and preserve reproductive function. This review considers methods of predicting and preventing recurrence of endometrial hyperplasia.

Keywords:endometrial hyperplasia; recurrent endometrial hyperplasia; prognosis; endometrial cancer; risk factors

REFERENCES

1. He Y., Wang Y., Zhou R., et al. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer. Int J Gynecol Cancer Published Online. 2020. October 13. DOI: https://doi.org/10.1136/ijgc-2020-001570

2. Orazov M.R., Mikhaleva L.M., Mullina I.A. Endometrial hyperplasia: a modern view of the problem. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2022; 10 (3): 62–7. DOI: https://doi.org/10.33029/2303-9698-2022-10-3-62-67 (in Russian)

3. Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia – from pathogenesis to effective therapy. Akusherstvo i ginekologiya novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2021; 9 (3): 21–8. DOI: https://doi.org/10.33029/2303-9698-2021-9-3-21-28 (in Russian)

4. Emons G., Beckmann M.W., Schmidt D., et al. New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015; 75: 135–6.

5. Chen H., Strickland A.L., Castrillon D.H. Histopathologic diagnosis of endometrial precancers: Updates and future directions. Semin Diagn Pathol. 2022; 39 (3): 137–47. DOI: https://doi.org/10.1053/j.semdp.2021.12.001 Epub 2021 Dec 10. PMID: 34920905; PMCID: PMC9035046

6. Kaprin A.D., Starinsky V.V., Shakhzodova A.O. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI imeni P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2020: 252 p. (in Russian)

7. American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society, 2021.

8. Nees L.K., Heublein S., Steinmacher S., Juhasz-Böss I., Brucker S., Tempfer C.B., et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022; 306 (2): 407–21. DOI: https://doi.org/10.1007/s00404-021-06380-5 Epub 2022 Jan 10. PMID: 35001185; PMCID: PMC9349105.

9. Orazov M.R., Mihaleva L.M., Orekhov R.E., Mullina I.A. Prevention of endometrial hyperplasia without atypia in women of reproductive age. Gynecology. 2021; 23 (5): 454–8. DOI: https://doi.org/10.26442/20795696.2021.5.201217

10. Orbo A., Arnes M., Vereide A.B., Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2019; 123: 1512–9.

11. Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012; 207 (4): 266.e1–12.

12. MacLean J.A. 2nd, Hayashi K. Progesterone actions and resistance in gynecological disorders. Cells. 2022; 11 (4): 647. DOI: https://doi.org/10.3390/cells11040647 PMID: 35203298; PMCID: PMC8870180.

13. Sletten E.T., Arnes M., Lysa L.M., Larsen M., Orbo A. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: A retrospective cohort study. BJOG. 2019; 126: 936–43.

14. Gibson D.A., Saunders P.T. Estrogen dependent signaling in reproductive tissues – a role for estrogen receptors and estrogen related receptors. Mol Cell Endocrinol. 2012; 348 (2): 361–72.

15. van der Putten L.J.M., van Hoof R., Tops B.B.J., Snijders M.P.L.M., van den Berg-van Erp S.H., van der Wurff A.A.M., et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis. 2017; 38 (3): 329–35.

16. Travaglino A., Raffone A., Saccone G., et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstet Gynecol Scand. 2019; 98: 1086–99.

17. Travaglino A., Raffone A., Saccone G., et al. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018; 231: 104–10.

18. Uccella S., Zorzato P.C., Dababou S., Bosco M., Torella M., Braga A., et al. Conservative management of atypical endometrial hyperplasia and early endometrial cancer in childbearing age women. Medicina (Kaunas). 2022; 58 (9): 1256. DOI: https://doi.org/10.3390/medicina58091256 PMID: 36143933; PMCID: PMC9504942.

19. Sanderson P.A., Critchley H.O., Williams A.R., Arends M.J., Saunders P.T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017; 23 (2): 232–54.

20. D’Andrilli G., Bovicelli A., Paggi M.G., Giordano A. New insights in endometrial carcinogenesis. J Cell Physiol. 2012; 227 (7): 2842–6. DOI: https://doi.org/10.1002/jcp.24016 PMID: 22105917.

21. Slettenn E.T., Arnes M., Lysa L.M., Moe B.T., Straume B., Orbo A. Prediction of relapse after therapy withdrawal in women with endometrial hyperplasia: a long-term follow-up study. Anticancer Res. 2017; 37: 2529–36.

22. Dore M., Filoche S., Danielson K., Henry C. Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response? Gynecol Oncol Rep. 2021; 36: 100732. DOI: https://doi.org/10.1016/j.gore.2021.100732 PMID: 33718563; PMCID: PMC7933258.

23. Mittermeier T., Farrant C., Wise M.R. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020; 9 (9): CD012658. DOI: https://doi.org/10.1002/14651858.CD012658.pub2 PMID: 32909630; PMCID: PMC8200645.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)